Adenosine, an endogenous distress signal, modulates tissue damage and repair

Cell Death and Differentiation

Volumn 14, Issue 7, 2007, Pages 1315-1323

  Fredholm, B B ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

5' NUCLEOTIDASE; ADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR AGONIST; ADENOSINE A2B RECEPTOR; ADENOSINE A3 RECEPTOR; ADENOSINE DEAMINASE; ADENOSINE KINASE; AMPA RECEPTOR; CAFFEINE; CD39 ANTIGEN; CYCLIC AMP; DOPAMINE 2 RECEPTOR; G PROTEIN COUPLED RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 13; INTERLEUKIN 4; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; OXYGEN; PURINE P2Y RECEPTOR; THEOPHYLLINE; TOLL LIKE RECEPTOR; UNINDEXED DRUG; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ASTHMA; B LYMPHOCYTE; CELL PROTECTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMBINED IMMUNODEFICIENCY; DENDRITIC CELL; DIAGNOSTIC VALUE; DRUG TARGETING; EPILEPSY; HUMAN; MACROPHAGE; MONOCYTE; NONHUMAN; NUCLEOTIDE SEQUENCE; OXYGEN SUPPLY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RESPIRATORY DISTRESS; REVIEW; T LYMPHOCYTE; TUMOR VASCULARIZATION;

ADENOSINE; ANIMALS; ANOXIA; CYTOPROTECTION; HUMANS; INFLAMMATION; ISCHEMIC PRECONDITIONING; OXIDATIVE STRESS; RECEPTORS, PURINERGIC P1; REGENERATION; SIGNAL TRANSDUCTION;

EID: 34250770500     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/sj.cdd.4402132     Document Type: Review

References (78)

1. Linden J. Adenosine in tissue protection and tissue regeneration. Mol Pharmacol 2005; 67: 1385-1387.
2. Zimmermann H. Extracellular metabolism of ATP and other nucleotides. Naunyn Schmiedebergs Arch Pharmcol 2000; 362: 299-309.
3. Deussen A, Lloyd HG, Schrader J. Contribution of S-adenosylhomocysteine to cardiac adenosine formation. J Mol Cell Cardiol 1989; 21: 773-782.
4. MacDonald PE, Braun M, Galvanovskis J, Rorsman P. Release of small transmitters through kiss-and-run fusion pores in rat pancreatic beta cells. Cell Metab 2006; 4: 283-290.
5. Eltzschig HK, Eckle T, Mager A, Küper N, Karcher C, Weissmüller T et al. ATP release from activated neutrophils occurs via connexin 43 and modulates adenosine-dependent endothelial cell function. Circ Res 2006; 99: 1100-1108.
6. Okada SF, Nicholas RA, Kreda SM, Lazarowski ER, Boucher RC. Physiological regulation of ATP release at the apical surface of human airway epithelia. J Biol Chem 2006; 281: 22992-23002.
7. Robson SC, Wu Y, Sun X, Knosalla C, Dwyer K, Enjyoji K. Ectonucleotidases of CD39 family modulate vascular inflammation and thrombosis in transplantation. Semin Thromb Hemost 2005; 31: 217-233.
8. Picher M, Burch LH, Hirsh AJ, Spychala J, Boucher RC. Ecto 5′-nucleotidase and nonspecific alkaline phosphatase. Two AMP-hydrolyzing ectoenzymes with distinct roles in human airways. J Biol Chem 2003; 278: 13468-13479.
9. Deussen A, Schrader J. Cardiac adenosine production is linked to myocardial pO2. J Mol Cell Cardiol 1991; 23: 495-604.
10. Jonzon B, Fredholm BB. Release of purines, noradrenaline, and GABA from rat hippocampal slices by field stimulation. J Neurochem 1985; 44: 217-224.
11. Parkinson FE, Xiong W, Zamzow CR. Astrocytes and neurons: Different roles in regulating adenosine levels. Neurol Res 2005; 27: 153-160.
12. Harshfield MS. New insights into adenosine-receptor-mediated immunosuppression and the role of adenosine in causing the immunodeficiency associated with adenosine deaminase deficiency. Eur J Immunol 2005; 35: 25-30.
13. Boison D. Adenosine kinase, epilepsy and stroke: Mechanisms and therapies. Trends Pharmacol Sci 2006; 27: 652-658.
14. Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 2001; 53: 527-552.
15. Fredholm BB, Bättig K, Holmén J, Nehlig A, Zvartau EE. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 1999; 51: 83-133.
16. Johansson B, Halldner L, Dunwiddie TV, Masino SA, Poelchen W, Giménez-Llort L et al. Hyperalgesia, anxiety, and decreased hypoxic neuroprotection in mice lacking the adenosine A1 receptor. Proc Natl Acad Sci USA 2001; 96: 9407-9412.
17. Kong T, Westerman KA, Faigle M, Eltzschig HK, Colgan SP. HIF-dependard induction of adenosine A2B receptor in hypoxia. FASEB J 2006; 20: 2242-2250.
18. Fredholm BB, Chem Y, Franco R, Sitkovsky M. Aspects of the general biology of adenosine A2A signaling. Prog Neurobiol 2007 (in press).
19. Arslan G, Kull B, Fredholm BB. Anoxia redistributes adenosine A(2A) receptors in PC12 cells and increases receptor-mediated formation of cAMP. Naunyn Schmiedebergs Arch Pharmacol 2002; 365: 150-157.
20. Berne RM. Cardiac nucleotides in hypoxia: Possible role in regulation of coronary blood flow. Am J Physiol 1963; 204: 317-322.
21. Hansen PB, Schnermann J. Vasoconstrictor and vasodilator effects of adenosine in the kidney. Am J Physiol Renal Physiol 2003; 285 F590-F599.
22. Sun D, Samuelson LC, Yang T, Huang Y, Paliege A, Saunders T et al. Mediation of tubuloglomerular feedback by adenosine: Evidence from mice lacking adenosine 1 receptors. Proc Natl Acad Sci USA 2001; 98 9983-9988.
23. Brown R, Ollerstam A, Johansson B, Skött O, Gebre-Medhin S, Fredholm B et al. Tubuloglomerular feedback and increased plasma renin in adenosine A1 receptor-deficient mice. Am J Physiol Regul Integr Comp Physiol 2001; 281: R1362-R1367.
24. Tawfik HE, Schnermann J, Oldenburg PJ, Mustafa SJ. Role of A 1 adenosine receptors in the regulation of vascular tone. Am J Physiol Heart Circ Physiol 2005; 288: H1411-HI416.
25. Yang J-N, Tiselius C, Daré E, Johansson B, Valen G, Fredholm BB. Gender differences in mouse heart rate and body temperature and in their regulation by adenosine A1 receptors. Acta Phys 2007 (in press).
26. Ledent C, Vaugeois JM, Schiffmann SN, Pedrazzini T, El Yacoubi M, Vanderhaeghen JJ et al. Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2A receptor. Nature 1997; 388: 674-678.
27. Conti B, Sanchez-Alavez M, Winsky-Sommerer R, Morale MC, Lucero J, Brownell S et al. Transgenic mice with a reduced core body temperature have an increased life span. Science 2006; 314: 825-828.
28. Sherman MY, Gabai VL. Multiple thermometers in mammalian cells: Why do cells from homeothermic organisms need to measure temperature? Sci STKE 2006; 2006 (328): Pe16.
29. Giménez-Llort L, Fernández-Teruel A, Escorihuela RM, Fredholm BB, Tobena A, Pekny M et al. Mice lacking the adenosine A1 receptor are anxious and aggressive, but are normal learners with reduced muscle strength and survival rate. Eur J Neurosci 2002; 16: 547-550.
30. Fredholm BB, Chen JF, Masino SA, Vaugeois JM. Actions of adenosine at its receptors in the CNS: Insights from knockouts and drugs. Annu Rev Pharmacol Toxicol 2005; 45: 385-412.
31. Schotanus SM, Fredholm BB, Chergui K. NMDA depresses glutamatergic synaptic transmission in the striatum through the activation of adenosine A(1) receptors: Evidence from knockout mice. Neuropharmacology 2006; 51: 272-282.
32. Kochanek PM, Vagni VA, Janesko KL, Washington CB, Crumrine PK, Garman RH et al. Adenosine A1 receptor knockout mice develop lethal status epilepticus after experimental traumatic brain injury. J Cereb Blood Flow Metab 2006; 26: 565-575.
33. Fedele DE, Li T, Lan JQ, Fredholm BB, Boison D. Adenosine A(1) receptors are crucial in keeping an epileptic focus localized. Exp Neurol 2006; 200: 184-190.
34. Gauda EB, Northington FJ, Linden J, Rosin DL. Differential expression of A(2A), A(1)-adenosine and D(2)-dopamine receptor genes in rat peripheral arterial chemoreceptors during postnatal development. Brain Res 2000; 872: 1-10.
35. Monteiro EC, Ribeiro JA. Adenosine-dopamine interactions and ventilation mediated through carotid body chemoreceptors. Adv Exp Med Biol 2000; 475: 671-684.
36. Headrick JP, Hack B, Ashton KJ. Acute adenosinergic cardioprotection in ischemic-reperfused hearts. Am J Physiol Heart Circ Physiol 2003; 285: H1797-H1818.
37. Stein AB, Tang XL, Guo Y, Xuan YT, Dawn B, Bolli R. Delayed adaptation of the heart to stress: Late preconditioning. Stroke 2004; 35 (Suppl 1): 2676-2679.
38. Fryer RM, Auchampach JA, Gross GJ. Therapeutic receptor targets of ischemic preconditioning. Cardiovasc Res 2002; 55: 520-525.
39. Lankford AR, Yang J-N, Rose'Meyer R, French BA, Matherne GP, Fredholm BB et at. Effect of modulating cardiac A1 adenosine receptor expression on protection with ischemic preconditioning. Am J Physiol 2006; 290: H1469-H1473.
40. Schulte G, Sommerschild H, Yang J, Tokuno S, Goiny M, Lövdahl C et al. Adenosine A receptors are necessary for protection of the murine heart by remote, delayed adaptation to ischaemia. Acta Physiol Scand 2004; 182: 133-143.
41. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005; 438: 932-936.
42. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005; 438: 967-974.
43. Greenberg DA, Jin K. From angiogenesis to neuropathology. Nature 2005; 438: 954-959.
44. Frantz S, Vincent KA, Feron O, Kelly RA. Innate immunity and angiogenesis. Circ Res 2005; 96: 15-26.
45. Adair TH. Growth regulation of the vascular system: An emerging role for adenosine. Am J Physiol Regul Integr Comp Physiol 2005; 289: R283-R296.
46. Feoktistov I, Ryzhov S, Zhong H, Goldstein AE, Matofonov A, Zeng D et al. Hypoxia modulates adenosine receptors in human endothelial and smooth muscle cells toward an A2B angiogenic phenotype. Hypertension 2004; 44: 649-654.
47. Merighi S, Benini A, Mirandola P, Gessi S, Varani K, Leung E et al. Adenosine modulates vascular endothelial growth factor expression via hypoxia-inducible factor-1 in human glioblastoma cells. Biochem Pharmacol 2006; 72: 19-31.
48. Montesinos MC, Shaw JP, Yee H, Shamamian P, Cronstein BN. Adenosine A(2A) receptor activation promotes wound neovascularization by stimulating angiogenesis and vasculogenesis. Am J Pathol 2004; 164: 1887-1892.
49. Cronstein BN. Adenosine, an endogenous anti-inflammatory agent. J Appl Physiol 1994; 76: 5-13.
50. Lukashev D, Ohta A, Apasov S, Chen JF, Sitkovsky M. Cutting edge: physiologic attenuation of proinflammatory transcription by the Gs protein-coupled A2A adenosine receptor in vivo. J Immunol 2004; 173: 21-24.
51. Bours MJ, Swennen EL, Di Virgilio F, Cronstein BN, Dognelie PC. Adanosine 5′-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. Pharmacol Ther 2006; 112: 358-404.
52. Akkari R, Burbiel JC, Hockemeyer J, Müller CE. Recent progress in the development of adenosine receptor ligands as antiinflammatory drugs. Curr Top Med Chem 2006; 6: 1375-1399.
53. Fredholm BB. Purines and neutrophil leukocytes. Gen Pharmacol 1997; 28: 345-350.
54. Eltzschig HK, Thompson LF, Karhausen J, Cotta RJ, Ibla JC, Robson SC et al. Endogenous adenosine produced during hypoxia attenuates neutrophil accumulation: Coordination by extracellular nucleotide metabolism. Blood 2004; 104: 3986-3992.
55. Yang D, Zhang Y, Nguyen HG, Koupenova M, Chauhan AK, Makitalo M et al. The A2B adenosine receptor protects against inflammation and excessive vascular adhesion. J Clin Invest 2006; 116: 1913-1923.
56. Chen Y, Corriden R, Inoue Y, Yip L, Hashiguchi N, Zinkemagel A et al. ATP release guides neutrophil chemotaxis via P2Y2 and A3 receptors. Science 2006; 314: 1792-1795.
57. Fredholm BB, Assender JW, Irenius E, Kodama N, Saito N. Synergistic effects of adenosine A1 and P2Y receptor stimulation on calcium mobilization and PKC translocation in DDT1 MF-2 cells. Cell Mol Neurobiol 2003; 23: 379-400.
58. Hask G, Pacher P, Deitch EA, Vizi ES. Shaping of monocyte and macrophage function by adenosine receptors. Pharmacol Ther 2007; 113: 264-275.
59. Zemecke A, Bidzhekov K, Ozüyaman B, Fraemohs L, Liehn EA, Lüscher-Firzlaff JM et al. CD73/ecto-5′-nucleotidase protects against vascular inflammation and neointima formation. Circulation 2006; 113: 2120-2127.
60. Tsutsui S, Schnermann J, Noorbakhsh F, Henry S, Yong VW, Winston BW et al. A1 adenosine receptor upregulation and activation attenuates neuroinflammation and demyelination in a model of multiple sclerosis. J Neurosci 2004; 24: 1521-1529.
61. Sun CX, Young HW, Molina JG, Volmer JB, Schnermann J, Blackburn MR. A protective role for the A1 adenosine receptor in adenosine-dependent pulmonary injury. J Clin Invest 2005; 115: 35-43.
62. Schnurr M, Toy T, Shin A, Hartmann G, Rothenfusser S, Soellner J et al. Role of adenosine receptors in regulating chemotaxis and cytokine production of plasmacytoid dendritic cells. Blood 2004; 103: 1391-1397.
63. Ohta A, Sitkovsky M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 2001; 414: 916-920.
64. Sullivan GW, Fang G, Linden J, Scheld WM. A2A adenosine receptor activation improves survival in mouse models of endotoxemia and sepsis. J Infect Dis 2004; 189: 1897-1904.
65. Lappas CM, Sullivan GW, Linden J. Adenosine A2A agonists in development for the treatment of inflammation. Expert Opin Investig Drugs 2005; 14: 797-806.
66. Lappas CM, Rieger JM, Linden J. A2A adenosine receptor induction inhibits IFN-gamma production in murine CD4+ T cells. J Immunol 2005; 174: 1073-1080.
67. Lappas CM, Day YJ, Marshall MA, Engelhard VH, Linden J. Adenosine A2A receptor activation reduces hepatic ischemia reperfusion injury by inhibiting CD1d-dependent NKT cell activation. J Exp Med 2006; 203: 2639-2648.
68. Ohta A, Gorelik E, Prasad SJ, Ronchese F, Lukashev D, Wong MK et al. A2A adenosine receptor protects humors from antitumor T cells. Proc Natl Acad Sci USA 2006; 103: 13132-13137.
69. Caruso M, Holgate ST, Polosa R. Adenosine signalling in airways. Curr Opin Pharmacol 2006; 6: 251-256.
70. Tilley SL, Boucher RC. A1 antagonism in asthma: Better than coffee? J Clin Invest 2005; 115: 13-16.
71. Mohsenin A, Blackburn MR. Adenosine signaling in asthma and chronic obstructive pulmonary disease. Curr Opin Pulm Med 2006; 12: 54-69.
72. Sun CX, Zhong H, Mohsenin A, Morschl E, Chunn JL, Molina JG et al. Role of A2B adenosine receptor signaling in adenosine-dependent pulmonary inflammation and injury. J Clin Invest 2006; 116: 2173-2182.
73. Gu Q, Ruan T, Hong JL, Burki N, Lee LY. Hypersensitivity of pulmonary C fibers induced by adenosine in anesthetized rats. J Appl Physiol 2003; 95: 1315-1324.
74. Thiel M, Chouker A, Ohta A, Jackson E, Caldwell C, Smith P et al. Oxygenation inhibits the physiological tissue-protecting mechanism and thereby exacerbates acute inflammatory lung injury. PLoS Biol 2005; 3: E174.
75. Fredholm BB. Adenosine and neuroprotection. In: Green AR, Cross AJ (eds). Neuro-protective Agents and Cerebral Ischemia. Academic Press: London, 1996, pp 259-280.
76. Olsson T, Cronberg T, Rytter A, Asztély F, Fredholm BB, Smith ML et al. Deletion of the adenosine A1 receptor gene does not alter neuronal damage following ischaemia in vivo or in vitro. Eur J Neurosci 2004; 20: 1197-1204.
77. Chen JF, Huang Z, Ma J, Zhu J, Moratalla R, Standaert D et al. A(2A) adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. J Neurosci 1999; 19: 9192-9200.
78. Yu L, Huang Z, Mariani J, Wang Y, Moskowitz M, Chen JF. Selective inactivation or reconstitution of adenosine A2A receptors in bone marrow cells reveals their significant contribution to the development of ischemic brain injury. Nat Med 2004; 10: 1081-1087.